Showing results (451-460 of 607) with videos related to

Sort By:
Pageof 61
Pharmacoeconomics - Open|April 15, 2020
Do Rural Residents in China Understand EQ-5D-5L as Intended? Evidence From a Qualitative StudyFan Yang, Shan Jiang, Xiao-Ning He, et al.
Pharmacoeconomics - Open|August 14, 2021
Evidence-Based Medicine and Healthcare Quality in the Context of Information Failure: The Case of the UK Fertility SectorMinyan Zhu
Pharmacoeconomics - Open|August 13, 2021
Continuous Monitoring of Respiratory Rate with Wearable Sensor in Patients Admitted to Hospital with Pneumonia Compared with Intermittent Nurse-Led Monitoring in the United Kingdom: A Cost-Utility AnalysisMehdi Javanbakht, Maziar Moradi-Lakeh, Atefeh Mashayekhi, et al.
Pharmacoeconomics - Open|August 23, 2022
Public Preferences and Willingness to Pay for a COVID-19 Vaccine in Iran: A Discrete Choice ExperimentAlireza Darrudi, Rajabali Daroudi, Masud Yunesian, et al.
Pharmacoeconomics - Open|January 16, 2022
Prevalence and Cost of Care for Parkinson's Disease in Luxembourg: An Analysis of National Healthcare Insurance DataSusanne Schmitz, Michel Vaillant, Christell Renoux, et al.
Pharmacoeconomics - Open|November 30, 2021
Similarities and Differences in Health Technology Assessment Systems and Implications for Coverage Decisions: Evidence from 32 CountriesAnna-Maria Fontrier, Erica Visintin, Panos Kanavos
Pharmacoeconomics - Open|December 10, 2021
A Cost-Utility Analysis of Trabecular Bypass Devices Versus Usual Care for Patients With Open-Angle GlaucomaPaul R Healey, Dominic Tilden, Dan Jackson, et al.
Pharmacoeconomics - Open|September 6, 2022
What is the Economic Cost of Providing an All Wales Postpartum Haemorrhage Quality Improvement Initiative (OBS Cymru)? A Cost-Consequences Comparison with Standard CareMegan Dale, Sarah F Bell, Susan O'Connell, et al.
Pharmacoeconomics - Open|September 15, 2022
Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in CanadaMoogeh Baharnoori, Virender Bhan, Fraser Clift, et al.
Pharmacoeconomics - Open|September 26, 2022
Healthcare Costs Among Patients with Psoriasis Treated with Ixekizumab Versus Secukinumab in Real-World Settings Over 24 MonthsAndrew Blauvelt, Nianwen Shi, Russel Burge, et al.
Pageof 61